Articles tagged with Prostate Cancer
Scientists at Roswell Park Comprehensive Cancer Center have identified gatekeeper genes that allow prostate cancer to progress and resist treatment. The study highlights opportunities to prevent or reverse this process, offering new insights into lineage plasticity and its application in other types of cancers.
Researchers at Scripps Florida have identified a novel signaling circuit driving therapy resistance in advanced prostate cancer. Targeting the components of this circuit, such as the NF-kB pathway and microRNA miR-196b-3p, shows promise in blocking the expression of stem cell transcription factors that fuel aggressive tumor growth.
A new UCL-led phase III clinical trial found that vascular-targeted photodynamic therapy (VTP) can effectively kill cancer cells while preserving healthy tissue. Around half of patients treated with VTP went into complete remission, compared to 13.5% in the control group.
A study of three genes associated with prostate cancer found that men with inherited mutations are more likely to develop aggressive forms and die earlier. The study suggests that germline mutations in these genes can be used to predict risk for lethal prostate cancer.
A 15-year study of prostate cancer patients found little difference in mortality between those screened annually and those not screened. However, the data suggest that personalized screening strategies could identify men at higher risk of death from other diseases.
A DNA methylation biomarker called PITX2 has been identified as a reliable predictor of prostate cancer recurrence. The study found that patients with high PITX2 methylation levels were at significantly increased risk for recurrence. This breakthrough could lead to more personalized treatment strategies for prostate cancer patients.
A panel of urologists and radiologists recommends using prostate MRI and MRI targeted biopsy for patients with suspected prostate cancer despite a prior negative biopsy. The recommended guidelines aim to improve detection rates, accuracy, and treatment options for these patients.
A novel imaging agent, Zr-89-Df-IAB2M, has been shown to detect metastasis of prostate cancer in both bone and soft tissue lesions with high accuracy. The agent targets PSMA on the exterior of prostate cancer cells, allowing for faster and more accurate detection than conventional methods.
Researchers develop a novel method to track an antibody targeting the hormone receptor pathway involved in prostate cancer. The technique uses PET scans to detect and monitor disease progression in real-time, enabling personalized treatment guidance.
Researchers report good results in patients with metastatic prostate cancer using bipolar androgen therapy (BAT), which alternately floods and starves the body of testosterone. The treatment has been safe and effective, with PSA levels falling, tumors shrinking, and some men showing a complete remission.
A study by King's College London found that black men face barriers to participating in prostate cancer research, including mistrust of researchers and a preference for traditional medicines. The researchers suggest community-driven engagement and dissemination of reliable information as ways to improve inclusion.
A new study by Brigham Young University researchers may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. The computer model uses medical images to reproduce the growth patterns of prostate cancer on the anatomy of a patient's prostate.
The University of California, Irvine has received a $1.2 million grant to develop more effective ways for prostate cancer patients and their physicians to customize treatment. The two-year clinical study will use patient-reported disease burden and tumor biomarkers to evaluate the effectiveness of treatment.
A team of researchers has developed a new prediction model that uses crowdsourced data from 550 international researchers to provide more accurate prognosis for patients with metastatic castration-resistant prostate cancer. The model, called ePCR, was developed through a collaboration between 16 institutions and used a computational le...
A new study by researchers at the University of Victoria and Australia's National Drug Research Institute found a statistically significant dose-response relationship between alcohol intake and risk of prostate cancer. Current drinkers who consumed high volumes had an increased risk, even at low-volume drinking levels.
Researchers at The Wistar Institute found TRAP1 increases tumor cell proliferation and invasion while providing a potential new therapeutic target for prostate cancer. TRAP1 overexpression combined with PTEN loss led to aggressive invasive prostate cancer in mice.
Researchers have discovered that the NAALADL2 molecule, which indicates more aggressive prostate cancer, can also be used to guide treatments. This new marker has the potential to distinguish between slow-growing and fast-growing prostate cancers.
A study of 2386 men with localized prostate cancer found that second opinions did not affect treatment choice or quality of care. Men who sought second opinions due to dissatisfaction with their initial urologist were less likely to receive definitive treatment.
Following the USPSTF recommendation against population-based PSA screening, median biopsy volume per urologist decreased by 29% and RP volume decreased by 16%. Prostate cancer diagnostic and therapeutic practice patterns have shifted significantly.
A special issue of Future Oncology examines the latest breakthroughs in prostate cancer imaging, including multiparametric MRI and PET imaging. The issue aims to provide a comprehensive overview of the field's current state and future directions.
A SWOG study found widespread detection bias in prostate cancer biopsies, affecting younger, healthier men and those with family history or elevated PSA levels. Biases led to inconsistent results on risk factors, highlighting the need for rigorous data analysis and caution against assumptions.
Researchers at Indiana University have discovered a connection between the genetic mechanisms that trigger Ewing's sarcoma and prostate cancer. This finding could lead to the development of new treatments for patients with both diseases.
African American men have higher incidence and mortality rates of prostate cancer due to genetic factors and socioeconomic disparities. MNX1 is a new oncogene identified as more active in African American prostate cancer, which can lead to improved diagnostic tools and treatment approaches.
A new report suggests that well over half of American men with non-aggressive prostate cancer could choose to monitor their disease instead of seeking immediate radiation treatment or surgery. Active surveillance relies on regular blood tests, physical exams, and periodic biopsies to screen for tumor growth before therapy is considered.
A new retrospective study found that men with prostate cancer treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as those whose testosterone levels are not tampered with. The study used deidentified records from Stanford Medicine's clinical-research data warehouse and aggregated several f...
A new study found that androgen deprivation therapy for prostate cancer may be associated with an increased risk of dementia, particularly among older men. The study analyzed electronic medical records data and found a significant association between ADT use and dementia development.
A new study published in International Journal of Cancer found that men with prostate cancer who used snus were at increased risk of premature death. Snus users had higher levels of nicotine and exposure to carcinogens compared to never-users, suggesting a potential link between snus use and prostate cancer progression.
A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone found no significant survival gains compared to the placebo arm. Custirsen blocks clusterin production, which is involved in carcinogenesis and treatment resistance.
A five-year review of over 275,000 visits at UT Southwestern Medical Center showed that PSA testing remained unchanged despite revised guidelines discouraging its use. The study found slight increases in PSA levels after the guidelines were revised, but these had little clinical impact on treatment or results.
Researchers mapped patterns of prostate cancer recurrence using C-11 choline PET imaging and multiparametric MRI, identifying sites of recurrence that can be targeted for radiation therapy. Nearly two-thirds of men had recurrence limited to the pelvis, a potentially treatable area.
Researchers found that delivering higher doses of radiation over a shortened period was safe and associated with lower costs for patients with favorable-risk prostate cancer. The hypofractionated radiation therapy schedule demonstrated comparable quality of life outcomes to conventional radiation therapy.
NRG-RTOG 0232 study found no significant difference in 5-year progression-free survival between external beam radiation therapy plus brachytherapy and brachytherapy alone. The treatment combination also resulted in fewer late genitourinary effects, mostly noted in the brachytherapy only arm.
Researchers developed a new way to identify aggressive prostate cancer patients by analyzing their tumor's genetic pathways. The study found three subtypes of prostate tumors, with one subtype showing high disease progression and poor clinical outcomes.
A recent study suggests that the digital rectal exam (DRE) is no longer necessary for prostate cancer screening due to its limited effectiveness and potential risks. The DRE has been shown to capture an additional small population of men with significant prostate cancer, but it also subjects a large number of men to unnecessary tests.
Researchers at Brigham and Women's Hospital found that PSA failure increases the risk of death by 1.6-fold in healthy men, but not those with comorbidities like heart disease or stroke. The study suggests healthy men should be informed about clinical trials showing reduced PSA failure benefits.
Researchers found that CHD1-depleted human prostate cancer cells are hypersensitive to DNA breaks and chemotherapeutic drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted prostate cancer therapy.
Researchers at UT Southwestern Medical Center developed a novel MRI method that can detect low levels of zinc ions to differentiate between healthy and malignant prostate tissue. This technique has the potential to serve as a biomarker for tracking prostate cancer progression.
Rates of early prostate cancer have continued to drop since the USPSTF recommendation, with localized/regional-stage incidence rates declining by 6-19% from 2011 to 2013. The decrease is attributed to changes in PSA testing rates and potentially unknown risk factors.
A recent study published in Nature Genetics has identified 45 noncoding genes associated with prostate cancer development and progression. These genes, known as noncoding RNA, play a key role in activating the disease process.
Researchers at Umeå University found that men with very high-risk prostate cancer treated at hospitals with a high proportion of radical local treatment had only half the mortality risk compared to those treated at low-proportion hospitals. Radical local therapy may prolong life for these patients.
Researchers at Brigham and Women's Hospital found that African-American men treated with hormone therapy had a 77% higher risk of death compared to non-African American men. The study analyzed over 7,000 patients and found that the increased mortality rate was not due to prostate cancer.
Researchers developed a computational approach to identify individualized targets for therapy by analyzing patient-specific data and mapping complex networks of gene and protein interactions. The study provides insights into the mechanisms behind resistance to anti-androgen therapies and offers a tool for prioritizing effective drugs.
A new scheme improved prostate cancer prognosis by grouping men into 5 strata based on clinical measurements like PSA level, disease stage, and tumor grade. This method performed better in predicting cancer death compared to the current risk stratification system.
A new study published in The Journal of Urology found no association between phosphodiesterase type 5 inhibitors (PDE-5i) and reduced risk of developing prostate cancer. PDE-5i use was also not linked to lower or higher grade cancer types.
Scientists at Newcastle University have identified a group of molecules that can be targeted to slow tumor growth in prostate cancer patients. The research found that testosterone changes these molecules, making cancer cells more likely to survive and spread.
A new study published in The Journal of Urology found that non-Hispanic black men were more likely than white men to begin active treatment for low-risk prostate cancer, independent of clinical measures. Ethnicity influenced this decision, suggesting a need for greater attention to race/ethnicity in disease management.
A new trial has found that robotic and open prostate cancer surgeries achieve similar results in terms of quality of life indicators, urinary function, and sexual function. Longer-term follow-up is needed to assess the full impact on cancer survival.
A study identified two genetic variants associated with an increased risk of radiotherapy side-effects in prostate cancer patients, including rectal bleeding and urinary frequency. The findings suggest that these variants are located in genes expressed in tissues exposed to radiation.
Researchers found that patients on active surveillance for low risk prostate cancer experienced similar health-related quality of life as men without the disease. The study suggests that conservative management can be a safe option, allowing clinicians to counsel patients effectively about potential outcomes.
A study found significant differences in gene expression between African American and European American men with prostate cancer, highlighting racial disparities. Vitamin D supplementation reduced these disparities, suggesting a therapeutic potential for addressing racial disparities in prostate cancer outcomes.
Researchers developed an analog of an investigational drug that binds to portions of the androgen receptor common to full-length and variant forms. This compound specifically detected prostate cancer cells expressing androgen receptor in a mouse model using SPECT/CT imaging.
A significant increase in metastatic prostate cancer cases has been observed, particularly among men aged 55-69. This rise is attributed to changes in screening practices and highlights the need for refining prostate cancer screening and treatment in the US.
A recent study by Northwestern University found that metastatic prostate cancer cases have increased by 72% between 2004 and 2013, with men aged 55-69 being disproportionately affected. The study suggests that both more aggressive disease and lax screening may be contributing factors.
A new pilot study evaluates an online decision-support tool called the Decision Counseling Program, which increases rates of active surveillance among men with localized, low-risk prostate cancer. Patients who used the tool reported feeling less conflicted about their treatment decisions.
Researchers at the OHSU Knight Cancer Institute have reported promising results from a Phase II clinical trial of pembrolizumab, a PD-1 antibody, in men with metastatic prostate cancer. Three out of ten participants showed significant responses to treatment, including rapid decreases in PSA levels and tumor shrinkage.
Researchers at Moffitt Cancer Center will investigate prostate cancer metastasis using a multi-disciplinary approach that integrates molecular, cellular and clinical information into mathematical models. The goal is to better understand the key factors driving disease progression and identify new therapeutic targets for prevention.
A new PET/MRI imaging test has been shown to improve the detection of significant prostate cancer, surpassing current multi-parametric MRI methods. The test's addition of molecular imaging based on F-18-choline positron emission tomography (PET) significantly improves the identification of clinically significant cancers.
A study of over 50,000 brothers of men with prostate cancer found that those with a family history were at increased risk of developing the disease. The risk was particularly high for those with an affected father or brother, and may be underestimated due to lack of awareness.
Researchers found that men with brothers who have had prostate cancer are twice as likely to develop the disease, while those with both a father and brother have a threefold risk. Early screening for these men is recommended starting at age 40.
A study found that over 10% of men with metastatic prostate cancer have inherited mutations in DNA repair genes, more than four times the general population rate. These mutations could benefit from targeted treatment already approved for ovarian cancer patients.